Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lexicon reports positive results of Phase I arthritis trial
LX2931 is one of four programs in human clinical trials as part of Lexicon’s 10TO10 program. Initial results from this single ascending-dose trial in healthy volunteers demonstrated a
LX2931 is one of four programs in human clinical trials as part of Lexicon’s 10TO10 program. Initial results from this single ascending-dose trial in healthy volunteers demonstrated a
The company reported that the Health Canada’s Therapeutic Products Directorate (TPD), the authority that regulates pharmaceutical drugs and medical devices, has approved its use. The company plans to
The test manufactured by Response Biomedical runs on the new RAMP 200 Reader and will be marketed and sold worldwide exclusively by 3M Health Care as the 3M
The Essential Tremor – 2 (POET-2) program is a two-part registration program, the first part of which is a clinical study to enroll up to 90 subjects with
Advaxis has successfully created a new live Listeria-based vaccine that combines the immune activation of Advaxis’s Listeria platform with the antigen p53 tumor target (Adxs-LmddA159). Adxs-LmddA159 is an
This second Phase II trial will investigate the product as an adjunct to systemic antibiotic therapy for treating moderately infected ulcers, as defined according to Infectious Disease Society
Regulus will receive $20 million in upfront payments from GlaxoSmithKline (GSK), including a $15 million option fee and a $5 million note that will convert into Regulus common
In the study, animals treated with pemetrexed alone showed 9.7% tumor growth inhibition. Animals treated with lucanthone alone showed 20% tumor growth inhibition. Animals treated with a combination
The Phase II study utilizes a unique design intended to demonstrate prolonged time until disease progression in patients who achieved a response or stabilization in their disease following
Subject to final issuance by the US Patent and Trademark Office, the newly allowed claims will have a July 2016 expiration date. Gerald Proehl, president and CEO of